Centre for Addiction and Mental Health
33 Russell Street
Dr. Vichnevetski is the Director of the Industry Partnerships and Technology Transfer Office (IPTTO) at the Centre for Addiction and Mental Health (CAMH).
Dr. Vichnevetski has 10 years of experience working as a research scientist in the area of molecular genetics at the Russian Academy of Sciences. Her familiarity with the field of technology transfer was originally gained through experience working as a scientist and an inventor at the Institute of Chemical Physics, Russian Academy of Sciences. Klara's knowledge in this area was further developed through patenting of her invention during the graduate studies at the University of Toronto. She also had formal training in patent drafting and prosecution with a Toronto-based law firm prior to joining CAMH in 2000.
Dr. Vichnevetski's employment at CAMH included positions such as Research Contracts and Licensing Officer and Manager, Research Commercialization. In her current role at CAMH as the Director, Industry Partnerships and Technology Transfer, Klara authorizes the selection of CAMH discoveries for intellectual property (IP) protection and commercialization; leads efforts to protect CAMH's IP; facilitates the licensing of CAMH's developed technologies; negotiates agreements with industry; oversees the creation of new CAMH-based companies, promotes entrepreneurial culture at CAMH; provides fiscal management of technology transfer operations. She also has established and maintains a portfolio of multidimensional relationships for CAMH with key industries in biotechnology and pharmaceutical sectors, as well as with not-for-profit partners.
Highlights of Klara's work at CAMH includes creation of AssureRx Canada, a joint venture between CAMH and Assurex Health, a US-based biotech company, a global leader in psychiatric pharmacogenomics. Klara identified Assurex Health as a strategic commercialization partner and led CAMH team efforts to negotiate agreements required for the joint venture creation that will commercialize CAMH-developed pharmacogenomic markers and deliver unique pharmacogenomic services to Canadian patients. Klara is also responsible for creation of CAMH's patent portfolio, successful negotiation of 20 license and option agreements and development of 2014 CAMH-wide policy on Inventions Commercialization.
Dr. Vichnevetski holds a PhD in Molecular Genetics from the University of Toronto.